Information Provided By: 
Fly News Breaks for May 16, 2019
DRNA
May 16, 2019 | 07:04 EDT
SunTrust analyst Edward Nash lowered his price target on Dicerna to $20, adjusting his model to forecast higher R&D cost given the expected rising clinical trial expense to be incurred for "both the pivotal PH program as well as Phase I HBV program." The analyst maintains his Buy rating however, citing the company's position as an "RNAi therapeutics pure-play" with a differentiated strategy for rare diseases. Nash also notes the near-tripling of appreciation for shares of RNAi platform companies over the past year.
News For DRNA From the Last 2 Days
There are no results for your query DRNA
